Patients with and without prior urolithiasis have hypocitraturia and incident kidney stones while on topiramate

Urology

Volumn 77, Issue 2, 2011, Pages 295-298

  Kaplon, Daniel M ^a   Penniston, Kristina L ^a   Nakada, Stephen Y ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CITRATE POTASSIUM; CITRIC ACID; OXALIC ACID; TOPIRAMATE;

ARTICLE; BIOCHEMISTRY; CALCIUM URINE LEVEL; CLINICAL ARTICLE; HUMAN; HYPOCITRATURIA; METABOLIC DISORDER; NEPHROLITHIASIS; PRIORITY JOURNAL; TREATMENT DURATION; URINARY EXCRETION; URINE PH; URINE VOLUME; UROLITHIASIS;

ANTICONVULSANTS; CITRIC ACID; FEMALE; FRUCTOSE; HUMANS; KIDNEY CALCULI; MALE; METABOLIC DISEASES; RETROSPECTIVE STUDIES; UROLITHIASIS;

EID: 79551606607     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2010.06.048     Document Type: Article

References (19)

1. S.L. McElroy, and P.E. Keck Jr. Topiramate A.F. Schatzberg, C.B. Nemeroff, Essentials of Clinical Pharmacology 2006 American Psychiatric Publishing Washington, D.C
2. E.J. Lamb, P.E. Stevens, and L. Nashef Topiramate increases biochemical risk of nephrolithiasis Ann Clin Biochem 41 2004 166 169
3. A.G. Wasserstein, I. Rak, and R.A. Reife Nephrolithiasis during treatment with topiramate Epilepsia 36 Suppl 3 1995 153 [Abstract]
4. S.J. Wallace A comparative review of the adverse effects of anticonvulsants in children with epilepsy Drug Saf 15 1996 378 393
5. S.D. Shorvon Safety of topiramate: adverse events and relationships to dosing Epilepsia 37 1996 S18 S22
6. E. Perucca A pharmacological and clinical review on topiramate, a new antiepileptic drug Pharmacol Res 35 1997 241 256
7. J. Takhar, and R. Manchanda Nephrolithiasis on topiramate therapy Can J Psychiatry 45 2000 491 493
8. R.L. Kuo, M.E. Moran, D.H. Kim, H.M. Abrahams, M.D. White, and J.E. Lingeman Topiramate-induced nephrolithiasis J Endourol 16 2002 229 231
9. E.H. Kossoff, P.L. Pyzik, S.L. Furth, H.D. Hladky, J.M. Freeman, and E.P. Vining Kidney stones, carbonic anhydrase inhibitors, and the ketogenic diet Epilepsia 43 2002 1168 1171
10. B.J. Welch, D. Graybeal, O.W. Moe, N.M. Maalouf, and K. Sakhaee Biochemical and stone-risk profiles with topiramate treatment Am J Kidney Dis 48 2006 555 563
11. K.S. Walia, E.A. Khan, D.H. Ko, S.S. Raza, and Y.N. Khan Side effects of antiepilepticsa review Pain Pract 4 2004 194 203
12. S. Eggener, S.C. Kim, H.M. User, J. Pazona, and R.B. Nadler Urolithiasis associated with topiramate Int Braz J Urol 30 2004 29 30
13. D. Vega, N.M. Maalouf, and K. Sakhaee Increased propensity for calcium phosphate kidney stones with topiramate use Expert Opin Drug Saf 6 2007 547 557
14. B.W. Warner, C.A. LaGrange, T. Tucker, M. Bensalem-Owen, and V.M. Pais Jr Induction of progressive profound hypocitraturia with increasing doses of topiramate Urology 72 2008 29 32
15. M. Goyal, R.I. Grossberg, M.A. O'Riordan, and I.D. Davis Urolithiasis with topiramate in nonambulatory children and young adults Pediatr Neurol 40 2009 289 294
16. S. Poston, M. Dickson, M. Johnsrud, M.F. Rupnow, J.M. Gdovin, and T.J. Bramley Topiramate prescribing patterns among Medicaid patients: diagnosis, comorbidities, and dosing Clin Ther 29 2007 504 518
17. M.F. Mello, M.S. Yeh, J. Barbosa Neto, L.L. Braga, J.P. Fiks, and D.D. Mendes A randomized, double-blind, placebo-controlled trial to assess the efficacy of topiramate in the treatment of post-traumatic stress disorder BMC Psychiatry 29 2009 9 28
18. D.C. Klonoff, and F. Greenway Drugs in the pipeline for the obesity market J Diabetes Sci Technol 2 2008 913 918
19. C.T. Supuran, A. Di Fiore, and G. De Simone Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity Expert Opin Emerg Drugs 13 2008 383 392 (Pubitemid 351957352)